Axsome Therapeutics, Inc. is a biopharmaceutical company committed to developing innovative treatments for central nervous system (CNS) conditions. The company focuses on ailments such as depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's product pipeline includes AXS-05, AXS-07, AXS-12, and AXS-14, which aim to address unmet patient needs and improve quality of life. Axsome strives to turn patient needs into breakthrough discoveries, and its portfolio includes products like Auvelity and Sunosi. The company actively conducts research and development, evidenced by ongoing clinical trials and presentations at scientific congresses.